GB2478556A — A composition for use in the treatment of Birt-Hogg-Dubô sydrome
Assigned to Myrovlytis Technology Ventures Ltd · Expires 2011-09-14 · 15y expired
What this patent protects
A composition comprises an inhibitor of glucose metabolism for use in the treatment of Birt-Hogg-Dube syndrome. The inhibitor of glucose metabolism may be a glycolytic inhibitor, such as 2-deoxy-D-glucose. Alternatively, the inhibitor may be an inhibitor of lactate dehydrogenase …
USPTO Abstract
A composition comprises an inhibitor of glucose metabolism for use in the treatment of Birt-Hogg-Dube syndrome. The inhibitor of glucose metabolism may be a glycolytic inhibitor, such as 2-deoxy-D-glucose. Alternatively, the inhibitor may be an inhibitor of lactate dehydrogenase in pyruvate metabolism, such as oxamate.
Drugs covered by this patent
- Rapamune (sirolimus) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.